Vertex Pharmaceuticals Incorporated
VRTXLast close · Oct 16, 2026499.74−9.01 (−1.77%)
Market cap$126.7B
Key indicators
Revenue12.6B+10.2% on a year earlier
3.0B
4.2B
6.2B
7.6B
8.9B
9.9B
11.0B
12.0B
12.6B
13.2B
14.7B
16.5B
Fiscal year
FY201818
FY201919
FY202020
FY202121
FY202222
FY202323
FY202424
FY202525
TTMTTM
FY2026E26E
FY2027E27E
FY2028E28E
| Fiscal year | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | TTM | FY2026E | FY2027E | FY2028E |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Growth | ||||||||||||
| 3.0B | 4.2B+36.6% | 6.2B+49.1% | 7.6B+22.1% | 8.9B+17.9% | 9.9B+10.5% | 11.0B+11.7% | 12.0B+8.9% | 12.6B+10.2% | 13.2B | 14.7B | 16.5B | |
| — | 36.6% | 49.1% | 22.1% | 17.9% | 10.5% | 11.7% | 8.9% | 10.2% | 10.4% | 10.7% | 12.3% | |
| $8.09 | $4.51−44.3% | $10.29+128.2% | $9.01−12.4% | $12.82+42.3% | $13.89+8.3% | -$2.08−115.0% | $15.32+836.5% | $17.17+22.3% | $18.68 | $21.05 | $25.16 | |
| Profitability | ||||||||||||
| 20.8% | 28.8%+7.9 pt | 46.0%+17.3 pt | 36.7%−9.3 pt | 48.2%+11.5 pt | 38.8%−9.4 pt | -2.1%−40.9 pt | 34.8%+36.9 pt | 38.0%+3.6 pt | · | · | · | |
| 68.8% | 28.3%−40.5 pt | 43.7%+15.4 pt | 30.9%−12.8 pt | 37.2%+6.3 pt | 36.7%−0.5 pt | -4.9%−41.5 pt | 32.9%+37.8 pt | 35.0%+3.1 pt | · | · | · | |
| 47.3% | 19.3%−27.9 pt | 31.2%+11.9 pt | 23.2%−8.0 pt | 23.9%+0.7 pt | 20.6%−3.3 pt | -3.3%−23.9 pt | 21.2%+24.4 pt | — | · | · | · | |
| Cash | ||||||||||||
| 1.2B | 1.5B+27.2% | 3.0B+100.4% | 2.4B−19.5% | 3.9B+63.0% | 3.3B−15.0% | -790.3M−123.7% | 3.2B+504.1% | 3.8B+8.5% | · | · | · | |
| 38.5% | 35.9%−2.7 pt | 48.2%+12.4 pt | 31.8%−16.4 pt | 44.0%+12.2 pt | 33.8%−10.1 pt | -7.2%−41.0 pt | 26.6%+33.8 pt | 30.2%−0.5 pt | · | · | · | |
| Balance sheet | ||||||||||||
| 259.19M | 260.67M+0.6% | 263.40M+1.0% | 259.90M−1.3% | 259.10M−0.3% | 260.50M+0.5% | 257.90M−1.0% | 258.00M+0.0% | 255.20M−1.4% | · | · | · | |
E = analyst consensus (revenue and EPS only). TTM = the twelve months to Jun 30, 2026: the last fiscal year, plus the quarters since, less the same quarters a year earlier. From the 10-K and the 10-Qs since, as accepted by the SEC; the shaded column is the latest period.